|
4th International Symposium on Cancer Metastasis and the Lymphovascular System
|
1R13CA159759-01
|
$3,000
|
LEONG, STANLEY
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
??PK mediated melanoma stem cell oncolysis through non-redundant programmed cell
|
5F31CA154087-02
|
$27,960
|
Colunga, Aric
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
A comparison of interventions to teach melanoma patients' skin self-examination
|
1R01CA154908-01
|
$608,819
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A Patient Oriented Research Program for Surgical Oncologists
|
5K24CA138709-02
|
$117,557
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A program of immune-based treatments for cancer
|
5K24CA093670-09
|
$183,021
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
A10Tg mice, a model of MDSC development and function in a tumor free environment
|
1F31CA159877-01
|
$32,878
|
Saleem, Sheinei
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
aAPC-Mediated NKT cell Modulation to Enhance Cancer Immunotherapy
|
5K01CA131487-04
|
$103,105
|
Webb, Tonya
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-35
|
$7,696,742
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-35S1
|
$50,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academic Training in Medical Oncology
|
3T32CA009297-28S1
|
$66,919
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Academic Training in Medical Oncology
|
5T32CA009297-28
|
$316,308
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Accuracy in the Diagnosis of Melanoma & the Impact of Technology & Double Reading
|
1R01CA151306-01A1
|
$882,806
|
ELMORE, JOANN
|
UNIVERSITY OF WASHINGTON
|
|
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
|
1U10CA149950-01A1
|
$1,300,000
|
SLOAN, JEFF
|
MAYO CLINIC
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
3P01CA128913-04S1
|
$76,630
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
5P01CA128913-04
|
$2,017,261
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,298,263
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1
|
5R01CA104711-07
|
$381,343
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Akt3 Signaling as a Therapeutic Target
|
5R01CA127892-04
|
$303,925
|
ROBERTSON, GAVIN
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
|
3R01CA134891-02S1
|
$37,338
|
HILLHOUSE, JOEL
|
EAST TENNESSEE STATE UNIVERSITY
|
|
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
|
5R01CA134891-02
|
$589,090
|
HILLHOUSE, JOEL
|
EAST TENNESSEE STATE UNIVERSITY
|
|
Analysis of cap-dependent translational repression by microRNAs in oncogensis
|
1R01CA140986-01A2
|
$326,813
|
NOVINA, CARL
|
DANA-FARBER CANCER INSTITUTE
|
|
Analysis of Lag-3 in Regulatory T Cell Function and Immune Supression
|
5R01CA127153-04
|
$330,091
|
DRAKE, CHARLES
|
JOHNS HOPKINS UNIVERSITY
|
|
Analysis of the Signaling and Mechanical Cues Promoting Invasion in Melanoma
|
1U01CA155758-01A1
|
$434,658
|
LEVCHENKO, ANDRE
|
JOHNS HOPKINS UNIVERSITY
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$1,220,780
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy
|
5R00CA128825-04
|
$241,530
|
Pilon-Thomas, Shari
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
|
ZIA SC 004020
|
$2,586,956
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Antigenic Determinants on HLA-B7 and -A2
|
5R01CA134060-27
|
$559,645
|
ENGELHARD, VICTOR
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
|
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
|
5R01CA087025-08
|
$261,901
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Applying nanosecond pulse electric fields to treat skin cancer
|
5R01CA125722-04
|
$397,073
|
NUCCITELLI, RICHARD
|
BIOELECTROMED CORPORATION
|
|
Arginase Production in Cancer: Evading Immune Response
|
2R01CA107974-06A1
|
$279,922
|
OCHOA, AUGUSTO
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S1
|
$139,575
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S2
|
$75,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
5P30CA023074-33
|
$3,953,813
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Asymmetric Division and Self Renewal of Cancer Stem Cells
|
ZIA BC 011003
|
$170,206
|
Avital, Itzhak
|
CCR (NCI)
|
|
ATF2 in melanoma development and progression
|
4R01CA099961-08
|
$402,590
|
RONAI, ZE'EV
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Atlanta Regional Community Clinical Oncology Program (ARCCOP)
|
5U10CA045450-25
|
$482,599
|
SEAY, THOMAS
|
ST. JOSEPH'S HOSPITAL
|
|
Augmenting Melanoma Response to B-Raf V600E Targeting
|
5K22CA151638-02
|
$186,840
|
LO, ROGER
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
B-RAF Regulation of the Cell Cycle in Melanoma
|
5R01CA125103-05
|
$248,776
|
Aplin, Andrew
|
THOMAS JEFFERSON UNIVERSITY
|
|
B7-H1/PD-1 modulation in cancer therapy
|
5R01CA142779-02
|
$479,334
|
PARDOLL, DREW
|
JOHNS HOPKINS UNIVERSITY
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Beaumont Community Clinical Oncology Program
|
3U10CA095860-10S1
|
$140,000
|
Robertson, John
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Beaumont Community Clinical Oncology Program
|
5U10CA095860-10
|
$882,302
|
Robertson, John
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
|
5R21CA143832-02
|
$323,248
|
HODI, FRANK
|
DANA-FARBER CANCER INSTITUTE
|
|
Bifunctional T cell receptor based immunotherapeutics
|
5R44CA097550-07
|
$979,275
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
Biochemistry of Melanins and Photoprotection of the Skin
|
ZIA BC 010784
|
$304,508
|
Hearing, Vincent
|
CCR (NCI)
|
|
Biology of Melanoma Metastasis
|
2R01CA047159-20A2
|
$317,738
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
Biomarker Discovery for the Classification of Melanoma
|
5R01CA131524-04
|
$418,424
|
BASTIAN, BORIS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Biopsychosocial Relationships underlying Indoor Tanning Experience: Project BRITE
|
5R21CA134819-02
|
$177,869
|
HECKMAN, CAROLYN
|
FOX CHASE CANCER CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|